Further Support for Whole Cranberry Powder in the Prevention of Urinary Tract Infections in Women
The aim of the 6 month intervention trial was to assess the efficacy of a daily dose of 500 mg of PACran in women with a history of recurrent UTIs.
Jul 29 2011 --- Lallemand Health Ingredients (LHI) and Decas Botanical Synergies (DBS), a subsidiary of Decas Cranberry Products, Inc., are pleased to share the overall results of a second randomized clinical trial substantiating the efficacy of a premium PAC-standardized whole cranberry powder PACran in the prevention of recurrent urinary tract infections (UTI) in women. The new study followed Good Clinical Practice (GCP) and was conducted by the team of Dr Vidlar from the Department of Urology, University Hospital in Olomouc, Czech Republic. The first data was presented last week at the 15th annual PhytoPharm congress in Nuremberg and makes PACran the first and only PAC-standardized whole cranberry powder backed by two controlled clinical studies.
PACran is distributed in Europe by Lallemand Health Ingredients, and suitable for the formulation of clinically supported food supplements of all galenic forms.
Julie Rosenborg, Product manager for Cranberry Ingredients for Lallemand Health Ingredients commented: “A recent market study (source: Innova Market Insights, 2011) has ranked ‘proven‘ as number one health trend. We are pleased to offer our customer the Whole Cranberry Powder with the strongest pool of clinical evidence on the market and are ready to support them in the development and marketing of innovative products addressing the urinary health segment.”
The aim of the 6 month intervention trial was to assess the efficacy of a daily dose of 500 mg of PACran in women with a history of recurrent UTIs. 165 women in total participated in the randomized study (79 in the PACran group, 86 in the placebo group). During the six months of the trial, there were 22 UTI events in the placebo group vs. 11 in the PAcran group.
The recurrence rate for the cranberry group was 14.2%, vs. 25.7% in the placebo group. This corresponds to an absolute reduction in UTI recurrence of 15%. These data further validate that a 500 mg daily dose of PACran is effective in reducing the recurrence of urinary tract infections in women.
The previous clinical trial with PACran in UTI prevention was published in April 2011 (1) and showed that the daily consumption of 500 mg of PACran by women suffering from recurrent UTIs was effective in both reducing the number of E. coli positive subjects and ameliorating the symptoms of UTI in these subjects. This is further supported by ex vivo data from Rutgers University (New Jersey) showing that the consumption of 500 mg PACran conferred the same level of ex vivo urinary anti-adhesion activity against uropathogenic E. coli over a 24-hour period as 300 ml of Cranberry Juice Cocktail containing 36 mg Proanthocyandines.
“PACran has been built from the ground up to deliver cranberry in support of urinary tract health,” said Rahul Shinde, Research Scientist for Decas Botanical Synergies. “This is the second clinical trial to show positive results for PACran’s support for women with urinary health issues. These results build on the extensive library of science we have developed in support of PACran.”
PACran is the cranberry constituent in Lallemand’s innovative probiotic & cranberry combination product - Cysbiotic, – targeting womens’ health. Associating the documented probiotic strain Lactobacillus Rhamnosus R-11 and PACran in a capsule stable at room temperature, Cysbiotic is recommended to support urinary tract health and improve gastrointestinal health.
(1) Vidlar A, Vostalova J, Vacek J, Kosina P, Vrbkova J, Ulrichova J, Student V, Simanek V. A randomized double blind placebo controlled trial to evaluate the efficacy of cranberry powder as a prophylactic against recurrent urinary tract infections in women. Presented at the 15th annual PhytoPharm congress in Nuremberg, Germany July 25-27, 2011.
(2) K. Sengupta, K.V. Alluri, T. Golakoti, G.V. Gottumukkala, J. Raavi et al. A Randomized, Double Blind, Controlled Dose Dependent Clinical Trial to Evaluate the Efficacy of a Proanthocyandines Standardized Whole Cranberry (Vaccinium Macrocarpon) Powder on Infections of the Urinary Tract. Current Bioactive Compounds 2011.
